title: Beneficial effect of albuterol in congenital myasthenic syndrome with epsilon-subunit mutations.
abstract: Mutations in the epsilon subunit of the acetylcholine receptor (AChR) are a common cause of congenital myasthenic syndrome (CMS). Patients are usually treated with acetylcholinesterase inhibitors and 3,4-diaminopyridine with modest clinical benefit. We report 2 patients with CMS due to mutations in the AChR epsilon subunit. The first patient carries two heterozygous frameshift mutations, ε127ins5 and ε1293insG. The second patient is homozygous for the εC142Y mutation that curtails AChR expression to 22% of wild-type in HEK cells. Treatment with pyridostigmine and 3,4-diaminopyridine had a limited beneficial effect in the first patient, and the second patient became wheelchair-bound during therapy. The additional use of albuterol produced dramatic improvement in strength and in activities of daily living in both patients. The efficacy and safety of albuterol in patients who harbor identified low-expressor or null mutations in the epsilon or other subunits of AChR merits a well-designed clinical trial.
authors: Department of Neurology, Wolfson Medical Center, Holon and Tel Aviv University, Halochamin Street, Holon 58100, Israel. mesadeh@post.tau.ac.il
authors: Menachem
authors: M
authors: Sadeh
authors: Xin-Ming
authors: XM
authors: Shen
authors: Andrew G
authors: AG
authors: Engel
mesh_terms: D058666:Adrenergic beta-2 Receptor Agonists / Q000627:therapeutic use*; D000328:Adult; D000420:Albuterol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D020294:Myasthenic Syndromes, Congenital / Q000188:drug therapy* / Q000235:genetics; D011978:Receptors, Nicotinic / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; C504423:CHRNE protein, human; D011978:Receptors, Nicotinic; D000420:Albuterol